- Home
- FTAIM vs CRNX Comparison
FTAIM vs CRNX Comparison
Compare FTAIM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FTAIM
FTAI Aviation Ltd. 9.500% Fixed-Rate Reset Series D Cumulative Perpetual Redeemable Preferred Shares
Current Price
Current Price
Company Overview
Basic Information| Metric | FTAIM | CRNX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | 580 | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 4.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FTAIM | CRNX |
|---|---|---|
| Price | $26.67 | $48.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $71.00 |
| AVG Volume (30 Days) | N/A | ★ 1.1M |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,535,000.00 |
| Revenue This Year | N/A | $425.31 |
| Revenue Next Year | N/A | $943.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.74 |
| 52 Week Low | N/A | $24.10 |
| 52 Week High | N/A | $54.78 |
Technical Indicators
Market Signals| Indicator | FTAIM | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 58.52 |
| Support Level | $26.51 | $43.04 |
| Resistance Level | $27.02 | $49.75 |
| Average True Range (ATR) | 0.08 | 2.05 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 30.51 | 74.62 |
Price Performance
Historical ComparisonAbout FTAIM FTAI Aviation Ltd. 9.500% Fixed-Rate Reset Series D Cumulative Perpetual Redeemable Preferred Shares
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.